Myeloma cells also increase the activity of osteoclasts (cells that damage bone). In a study of over 200 people with multiple myeloma, 37% of subjects reported bone pain as their first symptom.

When he was 38, with a wife and 7-month-old at home, Gluck learned he had multiple myeloma, a cancer of the plasma cells that causes damage to bones, kidneys, and the immune system.

Survival in multiple myeloma has almost tripled since the mid-1990s, from about 3 years with conventional therapy to now 8-10 years with high-dose chemotherapy supported by autologous stem cell ...

Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are “hideously expensive,” Dr. June said, costing more than $100,000 a year.

Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who ...

Multiple myeloma is becoming an increasing global burden. In 2022, there were an estimated 188,000 new cases and 121,000 deaths worldwide.

Existing risk stratification models for multiple myeloma characterize patients as "high" or "low" risk based on measures of tumor burden. These models do not include genetic factors.

4. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390:301-313.

The Spanish Society of Hematology and Hemotherapy (SEHH) held its ninth “HematoAvanza” Outreach Conference at the Pazo de San Lorenzo in Santiago, Spain. The event brought together ...